The Life Sciences Report: Michael, we live with a regulatory process in drug development that lasts for years. It seems to consume investors as we watch a molecule go through the pipeline. Do you think investors place too much emphasis on pivotal trial data, advisory committee votes and Prescription Drug User Fee Act (PDUFA) outcomes when, in some cases, a product’s market potential might not even merit that amount of due diligence?
Michael Higgins: Yes. I think you’re dead on. The clinical and regulatory boxes have to be checked, of course, but quite often investors haven’t done … [visit site to read more]